Abattis Bioceuticals Corp. engages in the aggregation, integration, and investment in agricultural technologies and biotechnology services for the legal cannabis industry developing in Canada. The firm aggregates, incubates, integrates and invests in the natural health product and botanical drug development industry. The company operates through the segment of producing, licensing and marketing ingredients and formulas for use in the biopharma, nutraceutical, cosmetic and animal nutrition markets. The Company, through its subsidiaries, develops and commercializes natural health (nutraceutical) products, and conducts research and development to create plant-based (botanical) intellectual property and ingredients for the pharmaceutical and bioceutical markets, among others. The company offers products and services, such as botanical blends and formulas; cannabidiol ingredients; functional foods and beverages, and analytical services. The company is focused on creating botanical formulations, medical marijuana and specialized health products for pain caused by inflammation, and mental ailments.
Vinci SA の最大収益セグメントは VINCI Autoroutes, VINCI Airports, and Other Concessions で、最新の利益発表における収益は 13,094,000,000 です。地域別に見ると、France が Vinci SA の主要市場であり、収益は 30,787,000,000 です。